Drug Farm, a clinical-stage biopharmaceutical company announced that the US Food and Drug Administration (FDA) has granted Rare Paediatric Disease (RPD) Designation for the company’s alpha-kinase 1 (ALPK1) inhibitor, DF-003, to treat patients with...
To improve the provision of cancer services to Alabama communities, Clearview Cancer Institute and OneOncology, the nation's fastest-growing platform for independent oncology practices, announced the completion of their agreement...
BrainSee (Darmiyan, San Francisco, California) has received De Novo approval from the Food and Drug Administration (FDA) to utilize their first-in-class clinical test for the possible assessment of Alzheimer disease (AD). BrainSee is software...
Scientists at the University of Oxford in the United Kingdom have begun first-in-human vaccine trials for the deadly Nipah virus, which affects numerous Asian countries, including India. The trials of the ChAdOx1 NipahB vaccine will include 51...
The US Food and Drug Administration (FDA) has approved Merck's anti-PD-1 therapy, Keytruda, in conjunction with chemotherapy radiation therapy (CRT) for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics)...
ClinChoice, a leading worldwide Contract Research Organization (CRO), has expanded its global reach with the purchase of CSI Medical Research. CSI is a regional clinical CRO with professional staff and partners located across Southeast Asia (SEA)...
Lupin, a leading pharmaceutical company, stated that it has gotten approval from the US Food and medicine Administration to offer a generic medicine to treat migraines and hypertension. The Mumbai-based business has gained approval from the US...
Stada and Alvotech announced that the European Commission has granted marketing permission for Uzpruvo (AVT04), a biosimilar candidate to Stelara (ustekinumab). The unified marketing authorization for Europe's first ustekinumab biosimilar is valid...
The start of GenePHIT (Gene Phosphatase Inhibition Therapy), a phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF), has been announced by Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a...
The sales of gout therapies in the seven major markets (7MM: the US, 5EU, and Japan) are expected to grow at a compound annual growth rate (CAGR) of 8.8 percent from $4.6 billion in 2022 to $10.8 billion in 2032, in line with rising disease...
, CDSCO.jpg)
.jpg)